<div id="readability-page-1"><p><span>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report)</span> had its target price reduced by stock analysts at Bank of America  from $30.00 to $28.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a &#34;neutral&#34; rating on the stock. Bank of America's price target would suggest a potential upside of 25.44% from the stock's current price.</p><div><p><span></span><span>Get <strong>Hims &amp; Hers Health</strong> alerts:</span></p></div><ul><li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li></ul><p>Several other equities research analysts have also commented on HIMS. Morgan Stanley cut their price objective on Hims &amp; Hers Health from $40.00 to $21.00 and set an &#34;equal weight&#34; rating for the company in a research report on Tuesday, February 24th. BTIG Research  restated a &#34;neutral&#34; rating on shares of Hims &amp; Hers Health in a research report on Tuesday, May 12th. Weiss Ratings downgraded Hims &amp; Hers Health from a &#34;hold (c)&#34; rating to a &#34;sell (d)&#34; rating in a research report on Tuesday, May 12th. Citigroup lifted their price objective on Hims &amp; Hers Health from $24.00 to $28.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, May 12th. Finally, Leerink Partners lifted their price objective on Hims &amp; Hers Health from $17.50 to $25.00 and gave the stock a &#34;market perform&#34; rating in a research report on Monday, March 16th. Four analysts have rated the stock with a Buy rating, eleven have issued  a Hold rating and two have issued  a Sell rating to the company's stock. According to data from MarketBeat.com, Hims &amp; Hers Health currently has an average rating of &#34;Hold&#34; and a consensus price target of $29.37.</p><p><b>Get Our Latest Stock Report on Hims &amp; Hers Health</b></p><h2>Hims &amp; Hers Health Price Performance</h2><ul><li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li></ul><p>Shares of NYSE:HIMS traded up $0.03 during trading on Tuesday, hitting $22.32. 20,746,443 shares of the stock were exchanged, compared to its average volume of 32,920,871. The company has a fifty day moving average price of $23.92 and a two-hundred day moving average price of $28.60. The company has a market cap of $5.09 billion, a PE ratio of -248.40, a P/E/G ratio of 44.19 and a beta of 2.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims &amp; Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. </p><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analysts' expectations of $616.84 million. Hims &amp; Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims &amp; Hers Health's revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $0.20 EPS.  On average, analysts forecast that  Hims &amp; Hers Health will post 0.04 EPS for the current year. </p><h2>Insiders Place Their Bets</h2><ul><li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li></ul><p>In other news, CFO Oluyemi Okupe sold 36,922 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares of the company's stock, valued at $7,300,355.30. The trade was a 11.58% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of the business's stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider directly owned 299,368 shares of the company's stock, valued at $8,981,040. This represents a 3.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 204,857 shares of company stock valued at $5,285,706. Insiders own  11.76% of the company's stock. </p><h2>Institutional Trading of Hims &amp; Hers Health</h2><p>Several institutional investors have recently made changes to their positions in HIMS. Pathway Capital Management LP purchased a new position in  Hims &amp; Hers Health in the 3rd quarter valued at about $6,766,000.  Steadview Capital Management LLC raised its stake in  Hims &amp; Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company's stock worth $39,809,000 after acquiring an additional 311,845 shares during the period.  Farallon Capital Management LLC increased its stake in shares of  Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period.  BIT Capital GmbH increased its stake in shares of  Hims &amp; Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period.  Finally, State of Michigan Retirement System increased its stake in shares of  Hims &amp; Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock valued at $116,713,000 after purchasing an additional 678,600 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors. </p><h2>Key Stories Impacting Hims &amp; Hers Health</h2><p>Here are the key news stories impacting Hims &amp; Hers Health this week:</p><ul>   <li><span>Negative Sentiment: </span>Hims &amp; Hers announced and then upsized a private offering of 0.00% convertible senior notes due 2032 to $350 million from the originally planned $300 million, raising concerns about future dilution and the balance sheet. <i></i><span>Article Title</span></li>   <li><span>Neutral Sentiment: </span>The company said the capital will help preserve financial flexibility while funding international expansion, infrastructure, and AI platform investments, which could support longer-term growth. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>Media reports also highlighted investor concern that the move may be tied to the planned Eucalyptus buyout and broader growth initiatives, reinforcing the view that Hims &amp; Hers is leaning on debt to finance expansion. <i></i><span>Article Title</span></li> </ul><h2>About Hims &amp; Hers Health</h2> (Get Free Report)<p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.  </p><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p><h2>Read More</h2><ul><li>Five stocks we like better than Hims &amp; Hers Health</li><li>HIVE Weaponizes Power for an AI Pivot</li><li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li><li>Brady Corp Wires Up a Massive AI-Powered Breakout</li><li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HIMS

HIMZ

HIMY

<p>Bank of America has lowered its price target for Hims & Hers Health (NYSE:HIMS) from $30.00 to $28.00, maintaining a 'neutral' rating. This suggests a potential upside of 25.44% from the current price. Other analysts have also adjusted their ratings, with Morgan Stanley setting a target of $21.00 and Citigroup raising it to $28.00. Hims & Hers Health's stock is currently trading at $22.32.</p>

Market Beat

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

Defiance Leveraged Long +Income HIMS ETF

iShares Global Healthcare

SPDR S&P Health

iShares US Healthcare Providers

VG Health

Bank of America

Morgan Stanley

Citigroup

Novo Nordisk AS

Eli Lilly

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00